May. 1 at 1:50 PM
$AMLX complements a large pharma offerings on three fronts:1. glp-1 anatagonist, 2. ALS, 3. ASO platform! amx0115 which is trialled for ALS treatment is an ASO! aso's are mRNA latheay blockers, and amylyx already in the space. aso's can be used to target other diseases including cancers.
$LLY looking to make acquisitions, and they are not alone!